Compare AKR & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKR | DNLI |
|---|---|---|
| Founded | 1993 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 3.2B |
| IPO Year | 1996 | 2017 |
| Metric | AKR | DNLI |
|---|---|---|
| Price | $20.76 | $21.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | $22.33 | ★ $30.80 |
| AVG Volume (30 Days) | 981.9K | ★ 1.6M |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $410,757,000.00 | N/A |
| Revenue This Year | $7.71 | N/A |
| Revenue Next Year | $3.51 | $3,886.00 |
| P/E Ratio | $205.30 | ★ N/A |
| Revenue Growth | ★ 14.20 | N/A |
| 52 Week Low | $16.98 | $10.57 |
| 52 Week High | $23.46 | $23.77 |
| Indicator | AKR | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 54.65 | 59.74 |
| Support Level | $19.45 | $13.29 |
| Resistance Level | $21.21 | $23.77 |
| Average True Range (ATR) | 0.51 | 1.18 |
| MACD | 0.02 | 0.11 |
| Stochastic Oscillator | 34.43 | 76.51 |
Acadia Realty Trust is a real estate investment trust that specializes in the operation, management, leasing, renovation, and acquisition of shopping centers and mixed-use properties with retail components. The company operates through three segments: Core Portfolio segment consists primarily of high-quality retail properties located primarily in high-barrier-to-entry, densely-populated metropolitan areas with a long-term investment horizon; Investment Management segment holds primarily retail real estate in which the company co-invests with high-quality institutional investors; and Structured Financing segment consists of earnings and expenses related to notes and mortgages receivable Fees earned by the company as the general partner or managing member through Investment Management.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.